Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Co-infusion of mesenchymal stromal cells to prevent GVHD after allogeneic hematopoietic cell transplantation from HLA-mismatched unrelated donors after reduced-intensity conditioning: a double-blind randomized study and literature review.
Lombardo G, Lechanteur C, Briquet A, Seidel L, Willems E, Servais S, Baudoux E, Kerre T, Zachee P, Herman J, Janssen A, Muller J, Baron F, Beguin Y. Lombardo G, et al. Among authors: lechanteur c. Stem Cell Res Ther. 2024 Dec 3;15(1):461. doi: 10.1186/s13287-024-04064-w. Stem Cell Res Ther. 2024. PMID: 39627816 Free PMC article. Clinical Trial.
Feasibility of co-transplantation of umbilical cord blood and third-party mesenchymal stromal cells after (non)myeloablative conditioning in patients with hematological malignancies.
Planken S, De Becker A, Kerre T, Schoemans H, Baron F, Graux C, Van Riet I, Lechanteur C, Baudoux E, Schots R, Beguin Y; Transplant Committee of the Belgian Hematology Society.. Planken S, et al. Among authors: lechanteur c. Curr Res Transl Med. 2024 Dec;72(4):103466. doi: 10.1016/j.retram.2024.103466. Epub 2024 Aug 17. Curr Res Transl Med. 2024. PMID: 39213720 Clinical Trial.
Multipotent mesenchymal stromal cells as treatment for poor graft function after allogeneic hematopoietic cell transplantation: A multicenter prospective analysis.
Servais S, Baron F, Lechanteur C, Seidel L, Baudoux E, Briquet A, Selleslag D, Maertens J, Poire X, Schroyens W, Graux C, De Becker A, Zachee P, Ory A, Herman J, Kerre T, Beguin Y. Servais S, et al. Among authors: lechanteur c. Front Immunol. 2023 Feb 1;14:1106464. doi: 10.3389/fimmu.2023.1106464. eCollection 2023. Front Immunol. 2023. PMID: 36817464 Free PMC article.
Clinical and MRI Evolution After Local Injection of Bone Marrow-Derived Mesenchymal Stem Cells in Perianal Fistulae in Crohn's Disease: Results From a Prospective Monocentric Study.
Reenaers C, Gillard RP, Coimbra C, Gillard RM, Meunier P, Lechanteur C, Baudoux E, Boutaffala L, Beguin Y, Louis É. Reenaers C, et al. Among authors: lechanteur c. J Crohns Colitis. 2023 May 3;17(5):728-737. doi: 10.1093/ecco-jcc/jjac192. J Crohns Colitis. 2023. PMID: 36733215 Free article. Clinical Trial.
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial.
Grégoire C, Layios N, Lambermont B, Lechanteur C, Briquet A, Bettonville V, Baudoux E, Thys M, Dardenne N, Misset B, Beguin Y. Grégoire C, et al. Among authors: lechanteur c. Front Immunol. 2022 Jul 4;13:932360. doi: 10.3389/fimmu.2022.932360. eCollection 2022. Front Immunol. 2022. PMID: 35860245 Free PMC article. Clinical Trial.
45 results